See also this year's filing and all EDGAR filings for this company.
PDF Report 0001566044_2026_VYNE_Therapeutics_Inc.pdf
Logs
Graph
Absolute values for 0001566044, VYNE Therapeutics Inc
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 30,010,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 90,000 |
| 3 | remainder_Assets | 60,000 |
| 4 | LiabilitiesCurrent | 2,395,000 |
| 5 | LiabilitiesNoncurrent | 0 |
| 6 | remainder_Liabilities | 0 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 11,110,540 |
| 9 | ResearchAndDevelopmentExpense | 11,817,949 |
| 10 | remainder_Expenses | 4,000 |
| 11 | remainder_Revenues | 549,510 |
| 12 | remainder_NetIncome | 3,459,906 |
| 13 | remainder_ComprehensiveNetIncome | -13,618 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 30,160,000 |
| 1 | Liabilities | 2,395,000 |
| 2 | Expenses | 22,932,489 |
| 3 | Revenues | 549,510 |
| 4 | StockholdersEquity | 27,765,000 |
| 5 | NetIncome | -18,923,073 |
| 6 | ComprehensiveNetIncome | -18,929,882 |
| 7 | BaseVar | 29,755,262 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | 2.56 |
| 9 | EconomicCapitalRatio | 3.39 |
Edgar->Model Mapping
Feature Distribution
Change over Time
